Owing to the co-occurrence of ECD with LCH in 15% of patients with ECD and the discovery of BRAF mutations and of other MAP kinase pathway alterations, LCH and ECD belong to the “L” group in the 2016 revision of the classification of histiocytosis [28]. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.